Biotricity's Return On Capital Employed Overview
Portfolio Pulse from Benzinga Insights
Biotricity (NASDAQ:BTCY) reported Q4 sales of $2.74 million, up from $2.46 million in Q3, but earnings decreased 3.43% to a loss of $4.67 million. The company posted a Return On Capital Employed (ROCE) of 0.24% in Q4, indicating effective capital allocation. Biotricity's Q4 earnings per share of $-0.08 beat analyst predictions of $-0.09.
July 03, 2023 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biotricity's Q4 sales increased but earnings decreased. The company's ROCE of 0.24% indicates effective capital allocation. Q4 earnings per share beat analyst predictions.
Biotricity's increased sales and better-than-expected earnings per share are positive signs, but the decrease in earnings is a concern. The company's ROCE suggests effective capital allocation, which could lead to future growth. However, the mixed financial results make the short-term impact on the stock price uncertain.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100